About the Authors

Nancy J Sullivan, Devon J Shedlock, Ling Xu, Laurie Lamoreaux, Paul M Popernack, Zhi-Yong Yang, Mario Roederer, Richard A Koup, Gary J Nabel
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

Thomas W Geisbert, Joan B Geisbert
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America

Jerome H. H. V Custers, Maria G Pau, Jaap Goudsmit
Crucell Holland B.V., Leiden, Netherlands

Peter B Jahrling
Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

Corresponding Author

gnabel@nih.gov

Competing Interests

GJN: Intellectual property on gene-based vaccines for Ebola. NJS: Intellectual property on gene-based vaccines for Ebola. ZYY: Intellectual property on gene-based vaccines for Ebola. The company Crucell is developing an Ebola vaccine.

Author Contributions

NJS, TWG, JBG, DJS, LL, and PMP contributed to animal experiments. NJS, DJS, LL, and PMP contributed to immune analyses. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to experimental design. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to data evaluation. NJS, TWG, MGP, PBJ and GJN participated in writing of the paper. LX, JHHVC, ZYY, and MGP contributed to vector construction and production.